Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).

Eric D Bateman; Kenneth R Chapman; Dave Singh; Anthony D D'Urzo; Eduard Molins; Anne Leselbaum; Esther Garcia Gil

doi:10.1186/s12931-015-0250-2

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).

Eric D Bateman, Kenneth R Chapman, Dave Singh, Anthony D D'Urzo, Eduard Molins, Anne Leselbaum, Esther Garcia Gil

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting beta2-agonist (400/12 μg twice daily) achieves improvements in lung function greater than either monotherapy in patients with chronic obstructive pulmonary disease (COPD), and is approved in the European Union as a maintenance treatment. The effect of this combination on symptoms of COPD and exacerbations is less well established. We examined these outcomes in a pre-specified analysis of pooled data from two 24-week, double-blind, parallel-group, active- and placebo-controlled, multicentre, randomised Phase III studies (ACLIFORM and AUGMENT). METHODS: Patients ≥40 years with moderate to severe COPD (post-bronchodilator forced expiratory volume in 1 s [FEV1]/forced vital capacity

Original language	English
Journal	Respiratory research
Volume	16
DOIs	https://doi.org/10.1186/s12931-015-0250-2
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12931-015-0250-2

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)
Bateman, E. D. (Contributor), Chapman, K. R. (Contributor), Singh, S. (Contributor), D'Urzo, A. D. (Contributor), Molins, E. (Contributor), Leselbaum, A. (Contributor) & Garcia Gil, E. (Contributor), figshare , 2 Aug 2015
DOI: 10.6084/m9.figshare.c.3607748.v1, https://figshare.com/collections/Aclidinium_bromide_and_formoterol_fumarate_as_a_fixed-dose_combination_in_COPD_pooled_analysis_of_symptoms_and_exacerbations_from_two_six-month_multicentre_randomised_studies_ACLIFORM_and_AUGMENT_/3607748/1
Dataset

Cite this

Bateman, E. D., Chapman, K. R., Singh, D., D'Urzo, A. D., Molins, E., Leselbaum, A., & Gil, E. G. (2015). Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory research, 16. https://doi.org/10.1186/s12931-015-0250-2

@article{26560e0551fa4c4a933c7aea1b07e866,

title = "Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).",

abstract = "BACKGROUND: The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting beta2-agonist (400/12 μg twice daily) achieves improvements in lung function greater than either monotherapy in patients with chronic obstructive pulmonary disease (COPD), and is approved in the European Union as a maintenance treatment. The effect of this combination on symptoms of COPD and exacerbations is less well established. We examined these outcomes in a pre-specified analysis of pooled data from two 24-week, double-blind, parallel-group, active- and placebo-controlled, multicentre, randomised Phase III studies (ACLIFORM and AUGMENT). METHODS: Patients ≥40 years with moderate to severe COPD (post-bronchodilator forced expiratory volume in 1 s [FEV1]/forced vital capacity",

author = "Bateman, {Eric D} and Chapman, {Kenneth R} and Dave Singh and D'Urzo, {Anthony D} and Eduard Molins and Anne Leselbaum and Gil, {Esther Garcia}",

year = "2015",

doi = "10.1186/s12931-015-0250-2",

language = "English",

volume = "16",

journal = "Respiratory research",

issn = "1465-993X",

publisher = "BioMed Central Ltd",

}

TY - JOUR

T1 - Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).

AU - Bateman, Eric D

AU - Chapman, Kenneth R

AU - Singh, Dave

AU - D'Urzo, Anthony D

AU - Molins, Eduard

AU - Leselbaum, Anne

AU - Gil, Esther Garcia

PY - 2015

Y1 - 2015

N2 - BACKGROUND: The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting beta2-agonist (400/12 μg twice daily) achieves improvements in lung function greater than either monotherapy in patients with chronic obstructive pulmonary disease (COPD), and is approved in the European Union as a maintenance treatment. The effect of this combination on symptoms of COPD and exacerbations is less well established. We examined these outcomes in a pre-specified analysis of pooled data from two 24-week, double-blind, parallel-group, active- and placebo-controlled, multicentre, randomised Phase III studies (ACLIFORM and AUGMENT). METHODS: Patients ≥40 years with moderate to severe COPD (post-bronchodilator forced expiratory volume in 1 s [FEV1]/forced vital capacity

AB - BACKGROUND: The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting beta2-agonist (400/12 μg twice daily) achieves improvements in lung function greater than either monotherapy in patients with chronic obstructive pulmonary disease (COPD), and is approved in the European Union as a maintenance treatment. The effect of this combination on symptoms of COPD and exacerbations is less well established. We examined these outcomes in a pre-specified analysis of pooled data from two 24-week, double-blind, parallel-group, active- and placebo-controlled, multicentre, randomised Phase III studies (ACLIFORM and AUGMENT). METHODS: Patients ≥40 years with moderate to severe COPD (post-bronchodilator forced expiratory volume in 1 s [FEV1]/forced vital capacity

U2 - 10.1186/s12931-015-0250-2

DO - 10.1186/s12931-015-0250-2

M3 - Article

C2 - 26233481

SN - 1465-993X

VL - 16

JO - Respiratory research

JF - Respiratory research

ER -

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).

Abstract

UN SDGs

Access to Document

Fingerprint

Datasets

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)

Cite this